These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21930607)

  • 1. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
    J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
    Hatano H; Scherzer R; Wu Y; Harvill K; Maka K; Hoh R; Sinclair E; Palmer S; Martin JN; Busch MP; Deeks SG; Hsue PY
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):317-25. PubMed ID: 22918156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
    Nakanjako D; Ssinabulya I; Nabatanzi R; Bayigga L; Kiragga A; Joloba M; Kaleebu P; Kambugu AD; Kamya MR; Sekaly R; Elliott A; Mayanja-Kizza H
    Trop Med Int Health; 2015 Mar; 20(3):380-90. PubMed ID: 25441397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
    Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
    Paton NI; Goodall RL; Dunn DT; Franzen S; Collaco-Moraes Y; Gazzard BG; Williams IG; Fisher MJ; Winston A; Fox J; Orkin C; Herieka EA; Ainsworth JG; Post FA; Wansbrough-Jones M; Kelleher P;
    JAMA; 2012 Jul; 308(4):353-61. PubMed ID: 22820788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
    McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
    Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
    Capetti A; Landonio S; Meraviglia P; Di Biagio A; Lo Caputo S; Sterrantino G; Ammassari A; Menzaghi B; Franzetti M; De Socio GV; Pellicanò G; Mazzotta E; Soria A; Meschiari M; Trezzi M; Sasset L; Celesia BM; Zucchi P; Melzi S; Ricci E; Rizzardini G
    PLoS One; 2012; 7(7):e39222. PubMed ID: 22808029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
    Yukl SA; Shergill AK; McQuaid K; Gianella S; Lampiris H; Hare CB; Pandori M; Sinclair E; Günthard HF; Fischer M; Wong JK; Havlir DV
    AIDS; 2010 Oct; 24(16):2451-60. PubMed ID: 20827162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.
    Markowitz M; Evering TH; Garmon D; Caskey M; La Mar M; Rodriguez K; Sahi V; Palmer S; Prada N; Mohri H
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):140-7. PubMed ID: 24457632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
    Somsouk M; Dunham RM; Cohen M; Albright R; Abdel-Mohsen M; Liegler T; Lifson J; Piatak M; Gorelick R; Huang Y; Wu Y; Hsue PY; Martin JN; Deeks SG; McCune JM; Hunt PW
    PLoS One; 2014; 9(12):e116306. PubMed ID: 25545673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial.
    Kamwesiga J; Mutabazi V; Kayumba J; Tayari JC; Uwimbabazi JC; Batanage G; Uwera G; Baziruwiha M; Ntizimira C; Murebwayire A; Haguma JP; Nyiransabimana J; Nzabandora JB; Nzamwita P; Mukazayire E;
    AIDS; 2015 Jun; 29(9):1045-52. PubMed ID: 25870994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.
    Kamat A; Misra V; Cassol E; Ancuta P; Yan Z; Li C; Morgello S; Gabuzda D
    PLoS One; 2012; 7(2):e30881. PubMed ID: 22363505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
    Ananworanich J; Chomont N; Fletcher JL; Pinyakorn S; Schuetz A; Sereti I; Rerknimitr R; Dewar R; Kroon E; Vandergeeten C; Trichavaroj R; Chomchey N; Chalermchai T; Michael NL; Kim JH; Phanuphak P; Phanuphak N
    J Virus Erad; 2015; 1(2):116-122. PubMed ID: 26835516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The link between chronic cocaine use, B cell perturbations, and blunted immune recovery in HIV-infected individuals on suppressive ART.
    Cheng D; Luo Z; Fitting S; Stoops W; Heath SL; Ndhlovu LC; Jiang W
    NeuroImmune Pharm Ther; 2023 Mar; 2(1):71-79. PubMed ID: 37027536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy.
    Presti RM; Yeh E; Williams B; Landay A; Jacobson JM; Wilson C; Fichtenbaum CJ; Utay NS; Dube MP; Klingman KL; Estes JD; Flynn JK; Loftin A; Brenchley JM; Andrade A; Kitch DW; Overton ET
    Open Forum Infect Dis; 2021 Dec; 8(12):ofab550. PubMed ID: 34888397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tree-Based Methods for Discovery of Association between Flow Cytometry Data and Clinical Endpoints.
    Eliot M; Azzoni L; Firnhaber C; Stevens W; Glencross DK; Sanne I; Montaner LJ; Foulkes AS
    Adv Bioinformatics; 2009; 2009():235320. PubMed ID: 20145719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The erythrocyte sedimentation rate in HIV: a neglected parameter?
    Lowe DM
    AIDS; 2010 Nov; 24(18):2773-5. PubMed ID: 20827163
    [No Abstract]   [Full Text] [Related]  

  • 19. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV.
    Ouyang J; Yan J; Zhou X; Isnard S; Harypursat V; Cui H; Routy JP; Chen Y
    Front Immunol; 2023; 14():1173956. PubMed ID: 37153621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?
    Tincati C; Mondatore D; Bai F; d'Arminio Monforte A; Marchetti G
    Open Forum Infect Dis; 2020 Sep; 7(9):ofaa340. PubMed ID: 33005694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.